Chugai Pharmaceutical Co., Ltd

4519

JP3519400000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
4,852 ^JPY	-0.16%		-1.40%	-9.17%

Apr. 25	Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	MT
Apr. 24	Chugai Pharmaceutical's Profit Slightly Up in Q1	MT

Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials

March 27, 2024 at 08:02 am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Maruho Co., Ltd. (hereafter, Maruho) obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-IL-31 receptor A humanized monoclonal antibody Mitchga Subcutaneous Injection 30 mg Vials [generic name: nemolizumab (genetical recombination)] for the treatment for the following diseases in patients only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis (children aged 6 and

Latest news about Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5%	Apr. 25	MT
Chugai Pharmaceutical's Profit Slightly Up in Q1	Apr. 24	MT
Japan's Nikkei slips on caution ahead of US inflation data	Apr. 09	RE
Chugai Pharmaceutical to Allocate 594 Million Yen of Treasury Shares as Restricted Stock Compensation	Mar. 29	MT
Roche's Chugai Wins Japanese Approval for Piasky Injection	Mar. 27	MT
Jefferies Adjusts Chugai’s Price Target to 7,000 Yen From 6,200 Yen, Keeps at Buy	Mar. 04	MT
Interest Rates, Central Bank Outlooks Churn Asian Stock Markets	Feb. 26	MT
Nikkei extends record rally on pharma boost	Feb. 25	RE
Nikkei hits record high as index heavyweights advance	Feb. 25	RE
US Tech Outlook Boost Asian Stock Markets	Feb. 22	MT
Global markets live: Sanofi, ABB, Qualcomm, Roche, Shell...	Feb. 01
Chugai Pharmaceutical’s Profit Down 13% in 2023	Feb. 01	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Non-Audited Earnings Guidance for the Financial Year 2024	Feb. 01	CI
From scandal to delisting: Toshiba's long-running crisis	Dec. 19	RE
Jefferies Adjusts Chugai Pharmaceutical’s Price Target to 6,200 Yen From 5,400 Yen, Keeps at Buy	Dec. 14	MT
Transcript : Chugai Pharmaceutical Co., Ltd. - Pre Recorded Special Call	Nov. 27
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT
Chugai Pharmaceutical’s Attributable Profit down 13.9% in Fiscal due to One-Off Lump-Sum Settlement;Shares Shed over 2.6%	23-10-24	MT
Chugai Parent Roche Settles US Lawsuit Against Biogen Over Alleged Biosimilar Infringement	23-10-24	MT
Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Nine Months and Financial Year Ending December 31, 2023	23-10-24	CI
Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2023	23-10-24	CI
Roche, Biogen Settle US Patent Infringement Case Over Actemra Biosimilar	23-10-23	MT
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug	23-10-23	RE
Jefferies Adjusts Chugai Pharmaceutical's Price Target to 5,400 Yen From 5,200 Yen, Keeps at Buy	23-10-02	MT
Japan's Nikkei posts biggest one-day drop in a month, rate jitters weigh	23-09-28	RE

Chart Chugai Pharmaceutical Co., Ltd

Duration

Period

More charts

Company Profile

Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%).

Sector

Pharmaceuticals

Calendar

2024-06-26 - Ex-dividend day for dividende intermédiaire

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Chugai Pharmaceutical Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,852 JPY

Average target price

6,044 JPY

Spread / Average Target

+24.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHUGAI PHARMACEUTICAL CO., LTD	-9.17%	50.71B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Chugai Pharmaceutical Co., Ltd

Equities

4519

JP3519400000

Pharmaceuticals

Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials

EPS Revisions